What Butterfly Network Stock's BCI Licensing Deal Means For Shareholders

• Butterfly Network and Merge Labs disclosed a multi year licensing deal that gives Merge access to Butterfly’s Poseidon ultrasound on chip platform for brain computer interface development, with upfront and milestone payments, hardware commitments, technology access fees, and potential royalties on future commercial sales.
• The agreement makes Butterfly Network the exclusive CMOS MEMS ultrasound supplier to Merge, while preserving Butterfly’s ability to license its chip platform to other BCI players. This broadens the potential use cases for its core technology beyond handheld imaging.
• Next, the focus shifts to how this exclusive ultrasound on chip partnership for brain computer interfaces may reshape Butterfly Network’s broader investment narrative.

Surf 37 healthcare AI stocks that could benefit from the same push toward AI driven imaging and brain computer interface tools that is now in focus at Butterfly Network.

Butterfly Network Investment Narrative Recap

For Butterfly Network, the investment case centers on handheld ultrasound and AI software evolving into a much larger, higher margin software and semiconductor platform. The Merge Labs licensing deal fits that story, since it adds a potential royalty stream and validates the Poseidon chip beyond handheld imaging. The main near term swing factor still appears to be execution on large enterprise and medical school rollouts, along with adoption of Compass AI and clinical applications, rather than this single BCI agreement. The key near term risk remains high spending and continued operating losses if those larger contracts or renewals slow.

The recent decision to raise 2026 guidance after reporting revenue growth is the clearest operational reference point for this new BCI agreement. Guidance already incorporated momentum in enterprise deployments, AI tools such as Compass and ScanLab, and early initiatives such as HomeCare, where recurring software and services play a larger role than one off device sales. The Merge partnership aligns with that same thesis, since it depends on Butterfly’s chip and AI stack being attractive to third parties. If higher R&D and semiconductor spending outpaces license and subscription revenue, the loss profile could still weigh on the investment case.

There is, however, one operational consideration in the background of Butterfly Network’s expansion that...

Read the full Butterfly Network narrative to see the case behind these numbers.

Butterfly Network’s current analyst narrative points to revenues of US$221.4 million and earnings of US$26.9 million by 2029, based on an assumed 25.5% yearly revenue growth rate and an earnings change of roughly US$101.7 million from a loss of US$74.8 million today.

Butterfly Network's forecasts put fair value at $10.67 against a $7.36 share price, representing a 45% upside to its current price that could narrow fast.

Exploring Other Perspectives

One alternate view on Butterfly Network leans hard into the upside from AI and ecosystem adoption. Those bullish analysts were already modeling about US$243.7 million of revenue and US$28.7 million in earnings by 2029 before this BCI deal surfaced. You can treat this licensing news as a fresh reason to revisit both the optimistic and cautious scenarios.

To see how other investors are framing Butterfly Network’s upside and downside, compare its 5 other fair value estimates for Butterfly Network.

The Verdict Is Yours

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your Butterfly Network research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• See our latest analysis for Butterfly Network. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Butterfly Network's overall financial health at a glance.

Looking For More Ideas Beyond Butterfly Network?

If this Butterfly Network story has you thinking about where else AI, healthcare and shifting balance sheets could create opportunity, the Simply Wall St screener can help you build a wider watchlist without losing focus.

• If you want quality at a discount, scan through 49 high quality undervalued stocks that combine stronger fundamentals with lower implied expectations in their current prices.
• If capital preservation is front of mind, filter for 83 resilient stocks with low risk scores that score well on volatility, balance sheet strength and business predictability.
• If you care about resilience as much as return potential, work through the list of solid balance sheet and fundamentals (24 results) to see which companies pair healthier finances with more durable operating profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com